ACE2 and allergic asthma: This is further supported by a recent report showing that IL-17 antagonism lowers ACE2 (Pavel et al., 2021) (a receptor critically involved in SARS-CoV-2 cell entry) expression in psoriasis patients (Krueger et al., 2019), and that higher Th17 response has been associated with worse allergic asthma severity (Shi et al., 2011).